Summary of Study ST002984
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001859. The data can be accessed directly via it's Project DOI: 10.21228/M8DT65 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002984 |
| Study Title | Amino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19 |
| Study Summary | Effective early-stage markers for predicting which patients are at risk of developing SARS-CoV-2 infection have not been fully investigated. Here, we performed comprehensive serum metabolome analysis of a total of 83 patients from two cohorts to determine that the acceleration of amino acid catabolism within 5 days from disease onset correlated with future disease severity. Increased levels of de-aminated amino acid catabolites involved in the de novo nucleotide synthesis pathway were identified as early prognostic markers that correlated with the initial viral load. We further employed mice models of SARS-CoV2-MA10 and influenza infection to demonstrate that such de-amination of amino acids and de novo synthesis of nucleotides were associated with the abnormal proliferation of airway and vascular tissue cells in the lungs during the early stages of infection. Consequently, it can be concluded that lung parenchymal tissue remodeling in the early stages of respiratory viral infections induces systemic metabolic remodeling and that the associated key amino acid catabolites are valid predictors for excessive inflammatory response in later disease stages. |
| Institute | Graduate School of Medicine, Kyoto University |
| Department | Center for Cancer Immunotherapy and Immunobiology |
| Laboratory | Sugiura-lab |
| Last Name | Sugiura |
| First Name | Yuki |
| Address | Shogoin-Kawaramachi 53,, Sakyo-ku, Kyoto, Kyoto, 160-8582, Japan |
| yuki.sgi@gmail.com | |
| Phone | +818050027858 |
| Submit Date | 2023-11-16 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | lcd, raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-12-04 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO003090 |
| Collection Summary: | Residual serum samples for biochemical and immunological tests were collected from patients with suspected SARS-CoV-2 infection who underwent RT-PCR testing of nasopharyngeal swab or saliva samples at Keio University Hospital or Osaka Metropolitan University Hospital from March 2020 to January 2021. The diagnosis of COVID-19 was based on a positive RT-PCR test from a nasopharyngeal swab or saliva sample. The classification of severity was based on the Japanese Ministry of Health, Labour and Welfare’s classification of severity (criteria for evaluation by healthcare professionals) and was defined as follows: asymptomatic, no symptoms associated with COVID-19; mild disease, SARS-CoV-2-positive with no findings of pneumonia; moderate disease, SARS-CoV-2-positive with findings of pneumonia but not requiring a ventilator or intensive care unit (ICU) management; and severe disease, SARS-CoV-2-positive requiring ventilator or ICU management, including death attributed to COVID-19 during the treatment period. For a negative control, residual serum samples were collected from patients who underwent RT-PCR testing using nasopharyngeal swab fluid between April and May 2020 at Keio University Hospital and received negative RT-PCR test results, making them clinically unlikely to have COVID-19. The study included the early patient cohorts of waves 1, 2, and 3 of COVID-19 conducted in Japan from March to December 2020. For cohorts 1 and 2, patients were not excluded because of comorbidities, as the main objective was to include the greatest possible number of severe cases for which specimens were available early after disease onset. Cases in the mild and moderate groups were selected based on matching age and sex distribution with the severe group. No specific exclusions were made in any group during the study period, mainly because the number of samples was limited. Asymptomatic and mildly symptomatic patients were selected for inclusion by balancing the sex ratio. The higher proportion of males in the moderate and severe categories is due to the observed tendency for males to be more severely affected. This was particularly true for patients hospitalized during the study period. Sample collection and utilization were conducted under the approval of the Ethics Committee of the Keio University School of Medicine (approval numbers 20200059 and 20200063) and the Ethics Committee of Osaka Metropolitan University Graduate School of Medicine (approval number 2020-003). The use of residual samples was conducted on an opt-out basis based on the approval of the relevant ethics committees. All samples were stored at -80 °C. |
| Sample Type: | Blood (serum) |
| Storage Conditions: | -80℃ |
